"Lipoproteins" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Lipid-protein complexes involved in the transportation and metabolism of lipids in the body. They are spherical particles consisting of a hydrophobic core of TRIGLYCERIDES and CHOLESTEROL ESTERS surrounded by a layer of hydrophilic free CHOLESTEROL; PHOSPHOLIPIDS; and APOLIPOPROTEINS. Lipoproteins are classified by their varying buoyant density and sizes.
| Descriptor ID |
D008074
|
| MeSH Number(s) |
D10.532 D12.776.521
|
| Concept/Terms |
Lipoproteins- Lipoproteins
- Lipoprotein
- Circulating Lipoproteins
- Lipoproteins, Circulating
|
Below are MeSH descriptors whose meaning is more general than "Lipoproteins".
Below are MeSH descriptors whose meaning is more specific than "Lipoproteins".
This graph shows the total number of publications written about "Lipoproteins" by people in this website by year, and whether "Lipoproteins" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 2 | 1 | 3 |
| 1997 | 1 | 1 | 2 |
| 1999 | 1 | 0 | 1 |
| 2000 | 0 | 2 | 2 |
| 2001 | 2 | 2 | 4 |
| 2002 | 4 | 1 | 5 |
| 2003 | 2 | 3 | 5 |
| 2004 | 0 | 2 | 2 |
| 2005 | 0 | 3 | 3 |
| 2006 | 1 | 1 | 2 |
| 2007 | 3 | 3 | 6 |
| 2008 | 0 | 2 | 2 |
| 2009 | 2 | 1 | 3 |
| 2010 | 1 | 3 | 4 |
| 2011 | 4 | 0 | 4 |
| 2012 | 5 | 1 | 6 |
| 2013 | 4 | 1 | 5 |
| 2014 | 1 | 1 | 2 |
| 2015 | 1 | 2 | 3 |
| 2016 | 3 | 2 | 5 |
| 2017 | 1 | 1 | 2 |
| 2018 | 1 | 2 | 3 |
| 2019 | 3 | 2 | 5 |
| 2020 | 3 | 0 | 3 |
| 2021 | 3 | 1 | 4 |
| 2022 | 0 | 6 | 6 |
| 2024 | 0 | 1 | 1 |
| 2025 | 2 | 0 | 2 |
| 2026 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Lipoproteins" by people in Profiles.
-
Targeting Triglycerides in Cardiovascular Disease Prevention: Evidence, Mechanisms, and Emerging Therapies. Curr Cardiol Rep. 2026 Jan 03; 28(1):8.
-
Non-remnant triglyceride-rich lipoproteins due to lipoprotein lipase deficiency increase atherosclerosis in mice. Nat Commun. 2026 Jan 03; 17(1):1458.
-
Effect of Targeting ApoC-III With Plozasiran on Lipoprotein Particle Size and?Number?in?Hypertriglyceridemia. J Am Coll Cardiol. 2025 May 20; 85(19):1839-1854.
-
Atherogenic lipoproteins associate with loss of glycemic control in youth-onset type 2 diabetes: Results from the TODAY study. J Clin Lipidol. 2025 May-Jun; 19(3):628-637.
-
A Gram-negative-selective antibiotic that spares the gut microbiome. Nature. 2024 Jun; 630(8016):429-436.
-
World Heart Federation Cholesterol Roadmap 2022. Glob Heart. 2022; 17(1):75.
-
Association between remnant lipoprotein cholesterol, high-sensitivity C-reactive protein, and risk of atherosclerotic cardiovascular disease events in the Multi-Ethnic Study of Atherosclerosis (MESA). J Clin Lipidol. 2022 Nov-Dec; 16(6):870-877.
-
Sugar-Sweetened Beverage Consumption and Plasma Lipoprotein Cholesterol, Apolipoprotein, and Lipoprotein Particle Size Concentrations in US Adults. J Nutr. 2022 11; 152(11):2534-2545.
-
Effect of olezarsen targeting APOC-III on lipoprotein size and particle number measured by NMR in patients with hypertriglyceridemia. J Clin Lipidol. 2022 Sep-Oct; 16(5):617-625.
-
Apolipoprotein C-III reduction in subjects with moderate hypertriglyceridaemia and at high cardiovascular risk. Eur Heart J. 2022 04 06; 43(14):1401-1412.